Elephas Biosciences Corp
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2023 | $51 M | No. 4 | $50 to $250 million | equity | SEC | |
| Aug 2022 | $42 M | No. 3 | $10 to $50 million | equity | SEC | |
| Sep 2021 | $20 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| May 2021 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Elephas Biosciences Corp chose not to state its revenue in its newest notice of a funding round (Jan 2024).
SEC Form D · Jan 2024
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jan 2024
That is all the official record says: Elephas Biosciences Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Elephas Biosciences Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 17 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Maneesh K. Arora | Executive officer | Jan 2024 |
| Terrence K. Brady | Executive officer | Jan 2024 |
| Terrence P. Brady | Executive officer | Sep 2022 |
| Jonathan P. Oliner | Executive officer | Oct 2021 |
| Andrea K. Jackson | Director | Jan 2024 |
| Maneesh K. Arora | Director | Jan 2024 |
| Paul K. Berns | Director | Jan 2024 |
| Steven K. Galson | Director | Jan 2024 |
| Michelle B. Arora | Director | Oct 2021 |
| Maneesh K. Arora | Promoter | Oct 2021 |